Cara Therapeutics, Inc. Company Profile

17:06 EDT 4th September 2015 | BioPortfolio


News Articles [45 Associated News Articles listed on BioPortfolio]

Cara Therapeutics' (CARA) CEO Derek Chalmers on Q2 2015 Results - Earnings Call Transcript

Cara Therapeutics' (CARA) CEO Derek Chalmers on Q1 2015 Results - Earnings Call Transcript

Cara Therapeutics' (CARA) CEO Derek Chalmers on Q4 2014 Results - Earnings Call Transcript

Stifel ups Cara Therapeutics price target to $25

Stifel has raised its price target for Cara Therapeutics (NASDAQ:CARA) to $25 from $20 after the company announced positive top-line Phase 2 proof-of-concept data for IV-CR845 in uremic pruritus, or c...

Cara is itching for approval

Cara Therpeutics' stock soared on 23 July after the company announced positive mid-stage results for its anti-itch medication.

Cara gains on pruritus data

Cara Therapeutics Inc. (NASDAQ:CARA) gained $3.15 (20%) to $18.99 on Thursday after IV CR845 met the primary endpoint of a Phase II trial to treat uremic pruritus. The long-acting peripheral kappa opi...

FOPO nets $65.8mm for Cara Therapeutics

Cara Therapeutics Inc. (pain and dermatological conditions) netted $65.8mm in a follow-on public offering of 3.8mm shares for $18.60. The company will spend the money on clinical trials of the IV and ...

FOPO nets $75.7mm for Cara Therapeutics

Cara Therapeutics Inc. (pain and dermatological conditions) netted $75.7mm in a follow-on public offering of 4.3mm shares (including the overallotment) for $18.60. The company will spend the money on ...

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Protecting the 'Hood Against Tobacco

Among all racial/ethnic groups, African Americans have the greatest risk of becoming ill or dying from tobacco-related diseases. Because of this disproportionate disease burden, it is part...

Companies [4 Associated Companies listed on BioPortfolio]

CARA Therapeutics

Cara possesses both near-term clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's first patented compound, CR665, has enter...

Cara Therapeutics, Inc.

CARA THERAPEUTICS -- OU NAME

Instituto de Cirugía Maxilofacial e Implantología

Me es grato darles la bienvenida a la página web del INSTITUTO DE CIRUGIA MAXILOFACIAL E IMPLANTOLOGIA.El Instituto, fundado en Mayo del 2000, tiene como objetivo el tratamiento integral médico-quir...

More Information about "Cara Therapeutics, Inc." on BioPortfolio

We have published hundreds of Cara Therapeutics, Inc. news stories on BioPortfolio along with dozens of Cara Therapeutics, Inc. Clinical Trials and PubMed Articles about Cara Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cara Therapeutics, Inc. Companies in our database. You can also find out about relevant Cara Therapeutics, Inc. Drugs and Medications on this site too.


Advertisement
 
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record